TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Improving KIdney Transplantation With Cellular Therapy Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* able to consent, able to provide blood sample~Exclusion Criteria:~* unable to consent, life-expectancy less than 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: None

Study Arms:
- Healthy participants (Type: None): Volunteers with no kidney disease, autoimmune disease or major cardiovascular comorbidities
- Participants with kidney disease (Type: None): Includes patient with chronic kidney disease, dialysis or functioning transplant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Misoprostol for Reduction of Blood Loss During Fibroid Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting for abdominal myomectomy with documented uterine fibroids on pelvic imaging (pelvic ultrasound or MRI) within in last 12 months~* Age ≥ 18 years and ≤ 50 years~* Pre-operative hemoglobin \>8 g/dl~* Willing to have buccal administration of misoprostol or a placebo at least one hour pre-procedure.~* Ability to understand and the willingness to sign a written informed consent.~* Admissible medical/surgical history~* Can be previously treated with Depo-Lupron, Depo-Provera, or Oral Contraceptive pills~* Intraoperative use of vasopressin and uterine tourniquet is permissible~* Can have had prior Cesarean delivery~Exclusion Criteria:~* Patients who have had a prior abdominal myomectomy~* Post-menopausal women~* Patients with known bleeding/clotting disorders~* Patients with a history of gynecologic malignancy~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to misoprostol~* Any cases converted to abdominal hysterectomy or other additional elective surgical procedures performed at time of abdominal myomectomy will be excluded from data analysis~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Misoprostol (Type: EXPERIMENTAL): 25 patients undergoing abdominal myomectomy operation will receive two tablets of misoprostol (400 mcg) buccally one hour before the operation.
- Placebo (Type: PLACEBO_COMPARATOR): 25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Medico-economic Evaluation of Preoperative Cerebral Oximetry Monitoring During Carotid Endarterectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients (male-female) over 18 y.o.~* Presenting an internal carotid stenosis requiring surgery~* Mini Mental State Examination \>24 during preoperative examination~* Informed written consentExclusion Criteria:~Exclusion criteria:~* Severe renal failure or requiring dialysis~* Liver failure or cirrhosis (Child class ≥ B) or prothrombin activity\<50%~* Heart failure (NYHA ≥ III), left ventricular ejection fraction \< 40%, acute coronary syndrome,~* Associated surgery~* Pregnancy~* Contraindication to MRI~* History of allergy to modified gelatine or starch~* History of allergy to adhesive part of electrode

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- open NIRS (Type: EXPERIMENTAL): continuous per operative cerebral oximetry monitoring (using INVOS™ cerebral oximeter) associated with hemodynamic optimisation algorithm (excluding norepinephrine) if cerebral oximetry decrease more than 15% under the preoperative baseline
- Blinded NIRS (Type: SHAM_COMPARATOR): Continuously monitored with cerebral oximeter but this latter is blinded to the medical team, the alarm switch off , and patients are managed with the standard care of the centre

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Care China-Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients between the ages of 18 and 80 (inclusive) receiving CYPHER SELECT™+ Sirolimus-eluting Coronary Stent according to standard clinical practice when financially feasible~* The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.~* Patient has diagnosis of diabetes or is diagnosed with it before or during the index procedure hospitalization based on disease diagnosis criteria~Exclusion Criteria:~* Any contraindication to any of the following medications: aspirin, heparin, thienopyridines (clopidogrel/ticlopidine), stainless steel, contrast agents, or sirolimus~* An elective surgical procedure is planned that would necessitate interruption of antiplatelet drugs during the first 6 months post enrollment~* Cardiogenic shock~* Terminal illness with life expectancy \<1 year~* ST-segment elevation myocardial infarction within 7 days prior to the index procedure~* Any patient who received coronary stent(s) within 1 year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Diabetes patients with PCI (Type: None): this is single group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of prostate cancer on biopsy~* Locally advanced or metastasised prostate cancer in need of hormonal treatment.~* On LHRH analogue treatment for a minimum of 5 months (at inclusion)~* Having a female partner~* Patients and their partner are able to fill out questionnaires, attend group sessions and give consent~Exclusion Criteria:~* Serious psychiatric difficulties~* Life expectancy \< 12 months

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): None
- Control group (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Colon Investigation - Factors Determining Choice of Procedure

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients referred to colon investigation~* Patients must be 18 years or older~Exclusion Criteria:~* Patients not able to give a written consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Sup-ER Protocol RCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of brachial plexus injury at birth.~* Significant deficit in external rotation and/or supination of the affected limb based on clinical assessment using the Toronto Active Movement Scale at 6 weeks of age (External Rotation ≤ 2 and/or Supination ≤ 2)~* Tightness in Passive Range of Motion of external rotation: any angle of less than 180°.~* Age 6-8 weeks~Exclusion Criteria:~* Neuromuscular disorder~* Unwillingness or inability to comply with the requirements of the study protocol.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 8 Weeks
- Healthy Volunteers: f

Study Arms:
- Sup-ER protocol (Type: EXPERIMENTAL): Early shoulder repositioning (Sup-ER Splint)
- Control (Type: ACTIVE_COMPARATOR): Standard treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with thickened endometrium~* Abnormal uterine bleeding~Exclusion Criteria:~* Pregnant~* Active pelvic infection~* Pelvic inflammatory disease~* Blood clotting disorders~* Sexually transmitted disease~* Uterine perforation~* Recent cesarean section

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SonoBiopsy Catheter (Type: EXPERIMENTAL): None
- Endometrial biopsy catheter (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must have diagnosis of AD \>= 12 months according to the American Academy of Dermatology criteria.~* Participants must have moderate to severe AD at screening and randomization.~* Participants must have inadequate response to topical medications within 6 months of screening (or history of intolerance).~Exclusion Criteria:~* Participants must not have concurrent treatment with topical or systemic treatments for AD.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 50 mg LY3375880 (Type: EXPERIMENTAL): Induction Period:~Participants received 50 mg LY3375880 administered SC Q4W.
- 150 mg LY3375880 (Type: EXPERIMENTAL): Induction Period:~Participants received 150 mg LY3375880 administered SC Q4W.
- 600 mg LY3375880 (Type: EXPERIMENTAL): Induction Period:~Participants received 600 mg LY3375880 administered SC Q4W.
- Placebo (Type: PLACEBO_COMPARATOR): Induction Period:~Participants received placebo administered subcutaneously (SC) every 4 weeks (Q4W).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinicopathological diagnosis of Waldenstrom's macroglobulinemia using consensus panel criteria~* Age 18 years or older~* CD20 positive based on any previous bone marrow immunohistochemistry or flow cytometric analysis~* All previous cancer therapy, including radiation, hormonal therapy and surgery, must have been discontinued at least 4 weeks prior to treatment in this study~* Measurable disease, defined as presence of immunoglobulin M paraprotein with a minimum IgM level of equal to or greater than 2 times the upper limit of normal.~* ECOG performance status of 0-2~* Absolute neutrophil count ≥ 100,000,000/L~* Platelet count ≥ 50,000,000,000/L~* Hemoglobin \> 8 g/dL~* Serum creatinine \< 2.5 mg/dL~* Total bilirubin \< 1.5 mg/dL~* AST and ALT \< 2.5 x ULN~* Disease free of prior malignancies fir 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast~Exclusion Criteria:~* Any serious medical condition, laboratory abnormality, or psychiatric illness~* Pregnant or lactating women~* Prior therapy with rituximab or CC-5103~* Known hypersensitivity to thalidomide~* Development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.~* Concurrent use of other anti-cancer agents or treatments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CC-5103 (Lenalidomide) and Rituximab (Type: EXPERIMENTAL): Intended therapy consisted of 48 weeks of CC-5103 (lenalidomide)(25 mg/d for 3 weeks and then 1 week off) along with rituximab (375 mg/m(2)/wk) dosed on weeks 2 to 5 and 13 to 16.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed or refractory DLBCL~* More than 1 line of prior chemotherapy~Exclusion Criteria:~* Currently receiving anticancer therapy or investigational agents~* Major surgery within last 4 weeks~* Known leptomeningeal or brain metastases~* Known HIV infection~* Uncontrolled fungal, bacterial, viral or other infection~* History of another malignancy (except for non-melanoma skin cancer or in situ cervical or breast cancer) unless disease free for at least 3 years~* Hepatitis B or C positive~* GI disease~* Pregnant or breastfeeding~* Prior treatment with an HDAC inhibitor including valproic acid

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Panobinostat/Rituximab (Type: EXPERIMENTAL): single-arm, open-label; Panobinostat with Rituximab: Panobinostat 40 mg orally 3 x weekly Rituximab 375 mg/m\^2 IV days 1,8,15,and 22 of cycle 1, and then on day 1 of subsequent cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Validation of a Walk-Time Limit Test (WTLT) Derived From the 6-Minute Walk Test (6-MWT) in Patients With Chronic Cardiovascular or Respiratory Diseases

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic Respiratory Disease Group:~  * Diagnosis of COPD with FEV1 corresponding to stages GOLD II or III (50-80% predicted or 30-50% predicted, respectively).~ * Patient's agreement~ * Being older than 18~ * Stable treatment for 3 months~ * Subjects affiliated with social security~* Group cardiovascular diseases:~  * Diagnosis of heart failure or stable coronary artery disease with NYHA Class II stage.~ * Patient's agreement~ * Being older than 18~ * Stable treatment for 3 months~ * Subjects affiliated with social security~Exclusion Criteria:~* Any medical contraindications to the practice of a suitable physical activity~* Presence of muscle, joint and / or neurological comorbidities affecting motor skills and test performance.~* Refusal of the patient~* Subject under guardianship or curatorship~* Subject aged over 80 at the time of inclusion~* Realization of a rehabilitation program during the study period~* Subject under resting oxygen therapy~* Diagnosis of heart failure, coronary artery disease or any cardiovascular pathology that required surgery.~* Diagnosis of an associated chronic respiratory disease, such as asthma, pulmonary arterial hypertension or interstitial lung disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Chronic Respiratory Disease Group (Type: EXPERIMENTAL): Each patient receive the same intervention : 4 visits with different exercise tests.~Visit 1: Inclusion Visit, Functional Assessment and TTLM Speed Determination (6-minute walk test x2, cardiopulmonary exercise testing on ergocycle, questionnaires and accelerometer)~Visit 2 : Functional Evaluation and Shuttle Tests (ISWT, ESWT, Speed tests on 4m, Quadriceps muscle strength)~Visit 3 : Feasibility of the WTLT (WTLT x2 or 3)~Visit 4 : Reproducibility of the WTLT (WTLT x2) Specific measures for COPD subjects : Respiratory Functional Assessment and Dyspnea questionnaire
- Cardiovascular diseases Group (Type: EXPERIMENTAL): Each patient receive the same intervention : 4 visits with different tests.~Visit 1: Inclusion Visit, Functional Assessment and TTLM Speed Determination (6-minute walk test x2, cardiopulmonary exercise testing on ergocycle,, questionnaires and accelerometer)~Visit 2 : Functional Evaluation and Shuttle Tests (ISWT, ESWT, Speed tests on 4m, Quadriceps muscle strength)~Visit 3 : Feasibility of the WTLT (WTLT x2 or 3)~Visit 4 : Reproducibility of the WTLT (WTLT x2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Estrogen Priming to Increase the Efficacy of Adjuvant Chemotherapy in Operable Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Patients with histological or cytologic proof of breast cancer. 2. Patients with operable breast cancer. 3. Patients who are candidates for adjuvant chemotherapy according to the standard policy. 4. Patients who have no contraindication to anthracycline based chemotherapy. 5. Patients who give informed consent to participate in the study. 6. Patients who can be followed up and can take all cycles of chemotherapy at the participating institution. 7. Patients should not have a known second cancer, present or past.~Exclusion Criteria:~-

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm B- Experimental (Type: EXPERIMENTAL): Tab Premarin 0.625 mg (Ethinyl estradiol) once a day for 5 days prior to each cycle of chemotherapy
- Arm A - Placebo (Type: PLACEBO_COMPARATOR): Tab Placebo once a day for 5 days prior to each cycle of chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Axillary lymph node dissection within the preceding 12 months~Exclusion Criteria:~* Patients with active cancer~* Patients with lymphedema~* Infection or bleeding tendency~* Patients with medical contraindications to nonsteroidal anti-inflammatory drugs (NSAIDs), including history of allergies, know gastrointestinal intolerance~* Other serious systemic illness (e.g., renal failure, hepatic dysfunction, congestive heart failure, neurological or psychological impairment) that would impair the patients' ability to participate~* Persons not competent to consent~* Patients on aspirin therapy~* Minors (\< 18 years of age)~* Pregnant and/or lactating women~* Males

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- (RS)2-(3-benzoylphenyl)-propionic acid (Type: EXPERIMENTAL): Patients receive study drug PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.~Laboratory biomarker analysis will be performed.
- placebo for study drug (Type: PLACEBO_COMPARATOR): Patients receive placebo PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.~Laboratory biomarker analysis will be performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues